JP2005505616A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505616A5
JP2005505616A5 JP2003536195A JP2003536195A JP2005505616A5 JP 2005505616 A5 JP2005505616 A5 JP 2005505616A5 JP 2003536195 A JP2003536195 A JP 2003536195A JP 2003536195 A JP2003536195 A JP 2003536195A JP 2005505616 A5 JP2005505616 A5 JP 2005505616A5
Authority
JP
Japan
Prior art keywords
methyl
pent
phenyl
ethoxy
ynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003536195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505616A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2002/000692 external-priority patent/WO2003033453A1/en
Publication of JP2005505616A publication Critical patent/JP2005505616A/ja
Publication of JP2005505616A5 publication Critical patent/JP2005505616A5/ja
Withdrawn legal-status Critical Current

Links

JP2003536195A 2001-10-17 2002-10-15 ジカルボン酸誘導体、それらの調製、並びに治療上の用途 Withdrawn JP2005505616A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101524 2001-10-17
PCT/DK2002/000692 WO2003033453A1 (en) 2001-10-17 2002-10-15 Dicarboxylic acid derivatives, their preparation and therapeutical use

Publications (2)

Publication Number Publication Date
JP2005505616A JP2005505616A (ja) 2005-02-24
JP2005505616A5 true JP2005505616A5 (enExample) 2006-01-05

Family

ID=8160773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003536195A Withdrawn JP2005505616A (ja) 2001-10-17 2002-10-15 ジカルボン酸誘導体、それらの調製、並びに治療上の用途

Country Status (11)

Country Link
EP (1) EP1438283A1 (enExample)
JP (1) JP2005505616A (enExample)
KR (1) KR20050036876A (enExample)
CN (1) CN1571766A (enExample)
BR (1) BR0213253A (enExample)
CA (1) CA2462514A1 (enExample)
HU (1) HUP0401837A2 (enExample)
IL (1) IL161170A0 (enExample)
PL (1) PL370244A1 (enExample)
RU (1) RU2004114875A (enExample)
WO (1) WO2003033453A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499380A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
DE60332860D1 (de) * 2002-10-28 2010-07-15 High Point Pharmaceuticals Llc Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
AU2003287912A1 (en) * 2002-12-20 2004-07-14 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
FR2850969B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Aminopropanediols acyles et analogues et leurs utilisations therapeutiques
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
EP1632245A1 (en) * 2004-09-02 2006-03-08 Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus ICA512 couples insulin secretion and gene expression in Beta-cells
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (en) * 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN109200043A (zh) * 2018-10-23 2019-01-15 华南农业大学 二羧酸(盐)在降低脂肪沉积和预防肥胖方面的应用
CA3185909A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
CN116003245B (zh) * 2022-12-21 2026-03-27 山东瑞健生物医药科技有限公司 一种2-羟基-3-氧代戊烷二酸的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331336A1 (fr) * 1975-11-14 1977-06-10 Rolland Sa A Acides oxy-4,4' bis(phenoxy-2 alcanocarboxyliques), leurs derives et leur application comme medicament
US5508296A (en) * 1991-07-30 1996-04-16 Yamanouchi Pharmaceutical Co., Ltd. Bisheterocyclic derivative or salt thereof
KR20020070508A (ko) * 2000-01-28 2002-09-09 노보 노르디스크 에이/에스 프로피온산 유도체 및 당뇨병 및 비만의 치료에 그것의 사용
PL357017A1 (en) * 2000-01-28 2004-07-12 Novo Nordisk A/S Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity

Similar Documents

Publication Publication Date Title
JP4790969B2 (ja) ペルオキシソーム増殖剤応答性受容体δの活性化剤
RU2004114875A (ru) Производные дикарбоновых кислот, их получение и терапевтическое применение
US6710063B1 (en) Activators of PPAR delta
US7649110B2 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7687526B2 (en) Benzo-fused compounds for use in treating metabolic disorders
US6867225B2 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
US20070066647A1 (en) Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US7358386B2 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20090163576A1 (en) Compounds for the treatment of metabolic disorders
CA2642662A1 (en) Compounds for the treatment of metabolic disorders
WO2002076957A1 (en) Activator for peroxisome proliferator-activated receptor
JPWO2002046176A1 (ja) ペルオキシソーム増殖剤応答性受容体の活性化剤
KR20010070966A (ko) 이상지혈증, 아테롬성 동맥 경화증 및 당뇨병의 치료에유용한 고리형 화합물, 약제학적 조성물 및 제조방법
US6288096B1 (en) Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
WO2004000785A2 (en) Phenyloxyalkanonic acid derivatives as hppar activators
WO2007085136A1 (en) 1,3-benzodioxolecyclopentene derivates, preparation process and medical uses thereof
JP4819801B2 (ja) ヘキセン酸誘導体、その調製方法、それらを含む医薬組成物およびその治療用途
US7157479B2 (en) Oxazol/thiazol-derivatives activators of the hPPAR-alpha receptor
RU2006119508A (ru) Бензаннелированные соединения в качестве активаторов ppar
US7141591B2 (en) 1,2,4-oxadiazole derivatives as hPPAR alpha agonists
JP2007522178A5 (enExample)
JP2007536291A (ja) ブタン酸誘導体、その調製方法、それらを含む医薬組成物およびその治療用途
JP2005503377A (ja) 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
US8541618B2 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JPWO2006126714A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤